BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Analyst Ratings
USA - NASDAQ:BDTX - US09203E1055 - Common Stock
3.87 USD
+0.05 (+1.31%)
3.86 USD
-0.01 (-0.26%)
ChartMill assigns a Buy % Consensus number of 86% to BDTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10. This target is 158.29% above the current price.
BDTX was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about BDTX.
In the previous month the buy percentage consensus was at a similar level.
BDTX was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-16 | Stifel | Reiterate | Buy |
| 2025-09-04 | Guggenheim | Initiate | Buy |
| 2025-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-01 | Raymond James | Reiterate | Outperform |
| 2025-03-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-07 | Stifel | Maintains | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-09-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-10 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-07-31 | Raymond James | Initiate | Outperform |
| 2024-07-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-06-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-07-14 | Piper Sandler | Initiate | Overweight |
| 2023-06-30 | Stifel | Upgrade | Hold -> Buy |
| 2023-06-28 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2023-06-27 | Stifel | Reiterate | Hold -> Hold |
| 2023-06-27 | Wedbush | Upgrade | Neutral -> Outperform |
| 2023-05-10 | Wedbush | Reiterate | Neutral |
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
What do analysts expect the price target to be for BLACK DIAMOND THERAPEUTICS I (BDTX)?
13 analysts have analysed BDTX and the average price target is 10 USD. This implies a price increase of 158.29% is expected in the next year compared to the current price of 3.87.
How do analysts rate BLACK DIAMOND THERAPEUTICS I (BDTX)?
The consensus rating for BLACK DIAMOND THERAPEUTICS I (BDTX) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for BLACK DIAMOND THERAPEUTICS I stock?
The number of analysts covering BLACK DIAMOND THERAPEUTICS I (BDTX) is 13.